Article: Long-term drug therapy and drug holidays for osteoporosis fracture prevention: A systematic review

Image
Description
Report co-written by Northwestern Health Sciences University researcher Mary Forte. The report was prepared by the Minnesota Evidence-based Practice Center for the Agency of Healthcare Research and Quality, U.S. Department of Health and Human Services in April 2019.
Abstract

Objective. To summarize the effects of long-term osteoporosis drug treatment (ODT) and ODT discontinuation and holidays on fractures and harms. 

 

Article: Treatment for acute pain: an evidence map

Image
Description
Article co-written by Northwestern Health Sciences University researcher Mary Forte. The article was prepared by the Minnesota Evidence-Based Practice Center and was prepared for the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services. It was published in October 2019. AHRQ Publication No. 19(20)-EHC022-EF.
Abstract

Introduction. Acute pain is a common ailment in the U.S. often treated with opioids. This technical brief maps the current evidence on pain treatments for select acute pain conditions (postdischarge postoperative pain, musculoskeletal pain, acute migraine, dental pain, renal colic, and acute pain associated with sickle cell disease).

 Methods. We conducted Key Informant discussions to develop the context around the acute pain conditions, settings, and current clinical practice. We then conducted a systematic literature search to identify recent systematic reviews of sufficient quality that evaluated pain treatments for select acute pain conditions. We screened results and extracted relevant data into evidence tables. We subsequently searched for original research published after systematic review search dates. 

Results. Key Informant discussions identified important issues regarding common acute pain conditions and treatments. Certain acute pain conditions have not received sufficient attention in rigorous comprehensive systematic review; for most types of acute pain, pain etiology is critical to selecting appropriate treatment; the value of acute pain assessments in guiding treatment decisions is unclear; and regional and health system level policies play a large role in treatment decisions. Our search for systematic reviews for pain treatments for priority acute pain conditions identified 1226 potentially relevant references, of which 527 underwent full text review. After supplemental searching and full text review, 110 systematic reviews met basic eligibility criteria. Most acute pain conditions had systematic reviews that met eligibility criteria, but few reviews were sufficiently rigorous and comprehensive. Few eligible reviews focused on specific settings except emergency departments for several acute pain conditions. Eligible reviews rarely addressed specific subpopulations such as racial and ethnic groups, rural residents, pregnant women, individuals with comorbidities, or those with a history of substance use disorder, overdose, or mental illness. Comparisons addressed by many systematic reviews often included opioids. 

Discussion. Our discussions with Key Informants and review of the literature show that additional original research and up-do-date comprehensive systematic reviews would help inform treatment decisions for a wide variety of acute pain conditions.

Article: Diagnosis and treatment of clinical Alzheimer's-type dementia: a systematic review

Image
Description
Article co-written by Northwestern Health Sciences University researcher Mary L. Forte. The article was prepared by the Minnesota Evidence-based Practice Center and was prepared for the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services. The article was made available online by the National Library of Medicine and the National Center for Biotechnology Information in 2020.
Abstract

Objective. To summarize evidence on: (1) the accuracy of brief cognitive tests for identifying clinical Alzheimer’s-type dementia (CATD) in individuals with suspected cognitive impairment; (2) the accuracy of biomarkers for identifying Alzheimer’s disease (AD) in individuals with dementia; and (3) the benefits and harms of prescription drugs and supplements for cognition, function, and behavioral and psychological symptoms of dementia (BPSD) in patients with CATD. 

 

Article: Benefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia: a systematic review and meta-analysis

Image
Description
The article was co-authored by Northwestern Health Sciences University researcher Mary L. Forte. The article was published in Annals of Internal Medicine and was published in 2020.
Abstract

Purpose:  To summarize evidence on the effects of prescription drugs and supplements for CATD treatment.

Conclusion:  Cholinesterase inhibitors and memantine slightly reduced short-term cognitive decline, and cholinesterase inhibitors slightly reduced reported functional decline, but differences versus placebo were of uncertain clinical importance. Evidence was mostly insufficient on drug treatment of BPSD and on supplements for all outcomes.